Association of baseline clinical factors with outcomes in patients with localized Ewing sarcoma treated on frontline trials with interval compressed chemotherapy (ICC): A report from the Children’s Oncology Group.
Ajay Gupta(Roswell Park Comprehensive Cancer Center), Leo Mascarenhas(University of Southern California), David S. Shulman(Harvard University), Damon R. Reed(Memorial Sloan Kettering Cancer Center), Richard Görlick(The University of Texas MD Anderson Cancer Center), Natalie DelRocco(University of Southern California), Katherine A. Janeway(Harvard University), Alexandra K. Callan(Southwestern Medical Center), Susan L. Whiteway(Uniformed Services University of the Health Sciences), Mark Krailo(Arcadia), Safia K. Ahmed(Mayo Clinic Hospital), Allen Buxton(Arcadia), Patrick J. Leavey(Children's Medical Center)
Cited by 0
Related Papers
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
The pediatric preclinical testing program: Description of models and early testing results
|Pediatric Blood & Cancer|2006|486
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419